

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**216403Orig1s000**

**OFFICER/EMPLOYEE LIST**

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
PUBLIC HEALTH SERVICE  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR DRUG EVALUATION AND RESEARCH

**DATE:** February 17, 2023

**TO:** Administrative file for NDA 216403

**FROM:** Anna Park, Regulatory Health Project Manager  
Division of Cardiology and Nephrology, Office of Cardiology, Hematology,  
Endocrinology & Nephrology (OCHEN)

**SUBJECT:** Officer/Employee List for NDA 216403

**APPLICATION/DRUG:** NDA 216403, FILSPARI (sparsentan) tablets, for oral use

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Abou-Sayed, Yasmeen  
Berger, Dan  
Booth, Benjamin  
Bourcier, Todd  
Cai, Lixia  
Cao, Christian  
Chandramouli, Sithamalli  
Chang, Suyoung Tina  
Datla, Srinivasa Raju  
DeConti, Selena  
Dinatale, Miriam  
Fromm, Edward  
Ghosh, Debasis  
Goulding, Margie  
Hariharan, Sudharshan  
Harris, Shelly  
Hayashi, Paul  
Jay, Christopher  
Ji, Yanyan  
Kambhampati, Rekha  
Kratz, Katherine  
Leginus, Joseph  
Liu, Hebing  
Liu, Jiang  
Lyons, Darrell  
Mandula, Haritha

Mayrosh, Ruth  
Mehta, Hina  
Monteleone, Michael  
Paradis, Joseph  
Park, Anna  
Sapru, Mohan  
Southworth, Mary Ross  
Stockbridge, Norman  
Thompson, Aliza  
Vee, Sarah  
Wachter, Lori  
Waites, Nancy  
Woronow, Daniel  
Wu, Jean  
Wyeth, Jo  
Yanoff, Lisa  
Zhang, Jialu